Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Vertex Pharmaceuticals

The Crispr Therapeutics (NASDAQ: CRSP) stock price moved sideways after the Food and Drug Administration (FDA) approved Casgevy. The shares were trading at $70.30 on Friday, where they have been in the past few days.

CRISPR, VRTX stock prices waver as US FDA approves Casgevy

bluebird bio

The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.

US approves two gene therapies for sickle cell disease

Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.

U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease

Crispr stock rose early Friday ahead of the FDA's expected approval of a groundbreaking gene-editing treatment.

Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment

CRISPR Therapeutics could commercialize its first medicine in the U.S. very soon. Yet, it laid off a significant portion of its workforce in advance of that possibility.

CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?

The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.

U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients

American Tower

Amazon

CrowdStrike

Alphabet

Lovesac Company

Okta

PayPal

Western Digital

There has been no shortage of next-big-thing trends for investors to latch onto over the past three decades. Some of this year's hottest trends, including artificial intelligence (AI) and electric vehicles (EVs), could falter in 2024.

5 Unstoppable Trends to Invest $1,000 in for 2024

Caribou Biosciences

Gilead Sciences

Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

CRISPR Therapeutics is cutting two of its more advanced candidates in favor of two next-generation ones. The company is also awaiting a key regulatory decision on Friday.

Is This News a Setback or a Step Forward for CRISPR Therapeutics?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?

The consensus price target hints at a 27.2% upside potential for CRISPR Therapeutics AG (CRSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 27.15%: Read This Before Placing a Bet

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

Invitae

CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals.

Better Growth Stock: CRISPR Therapeutics vs. Invitae

-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70-

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

ARK Genomic Revolution Multi-Sector ETF

Beam Therapeutics

Editas Medicine

Robinhood

Eli Lilly

Intellia Therapeutics

Prime Medicine Inc

Regeneron Pharmaceuticals

Verve Therapeutics

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

Intuitive Surgical

Pfizer

Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- are a good place to start.

5 Top Stocks to Buy Before 2024

AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovation. AI is turbocharging techniques like CRISPR and Prime Editing, opening doors to previously unimaginable genetic breakthroughs. In the AI-enhanced biotech arena, traditional valuation metrics are old news. Speed, efficiency, and the ability to leapfrog development stages redefine how we value these trailblazing firms.

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

ARK Innovation ETF

Coinbase

Microsoft

NVIDIA

Roku

Block

Twist Bioscience Corp

ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.

5 Best Performing Stocks of the Top ETF of November

Ginkgo Bioworks Holdings

These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.

Looking for Growth? 2 Top Stocks to Buy Hand Over Fist

Arcellx

In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.

3 Biotech Stocks That Could Be Multibaggers in the Making

Does CRISPR Therapeutics AG (CRSP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why CRISPR Therapeutics AG (CRSP) is a Great Momentum Stock to Buy

Crispr just executed on a moonshot goal, winning U.K. approval for the first-ever gene-editing treatment and sending CRSP stock sky-high.

What's Next For Gene-Editing Darling Crispr After Its 'Historic' First-Ever Approval?

Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline targeting various genetic diseases and conditions. CRSP focuses on ex vivo gene editing and has a diverse pipeline targeting different therapeutic areas, including hemoglobinopathies, immuno-oncology, and regenerative medicine.

CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics

Transmedics Group Inc

Amazon has plenty of room to grow despite its already huge size. CRISPR Therapeutics is at a pivotal point, with U.S. approvals for its lead candidate potentially on the way.

Investing in These 3 Stocks Now Could Make You a Millionaire Retiree

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for its simplicity and versatility. Major publicly traded CRISPR companies include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Caribou Biosciences, and Prime Medicine.

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

News for CRISPR Therapeutics Stock (CRSP)